PIK3CD and cervical adenocarcinoma: However, in patients with metastatic or recurrent adenocarcinoma of the cervix, there was no significant difference in OS associated with matched therapy in spite of a higher rate of SD ≥ 6 months/CR/PR and significantly longer PFS, which might be owing to at least three potential factors: lower prevalence of the activated PI3K/AKT/mTOR pathway, intrinsic sensitivity to novel phase I trial therapy available at MD Anderson phase I service, and the presence of PIK3CA mutation and/or PTEN loss/mutation that cannot stratify for aggressiveness of disease.